FR2844716A1 - NEW PHARMACEUTICAL COMPOSITIONS INTENDED IN PARTICULAR FOR DIABETIC FOOT HYGIENE - Google Patents
NEW PHARMACEUTICAL COMPOSITIONS INTENDED IN PARTICULAR FOR DIABETIC FOOT HYGIENE Download PDFInfo
- Publication number
- FR2844716A1 FR2844716A1 FR0211712A FR0211712A FR2844716A1 FR 2844716 A1 FR2844716 A1 FR 2844716A1 FR 0211712 A FR0211712 A FR 0211712A FR 0211712 A FR0211712 A FR 0211712A FR 2844716 A1 FR2844716 A1 FR 2844716A1
- Authority
- FR
- France
- Prior art keywords
- pharmaceutical compositions
- compositions according
- agent
- phenomena
- epidermal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 13
- 208000008960 Diabetic foot Diseases 0.000 title description 5
- 230000002421 anti-septic effect Effects 0.000 claims abstract description 5
- 230000018044 dehydration Effects 0.000 claims abstract description 5
- 238000006297 dehydration reaction Methods 0.000 claims abstract description 5
- 238000011321 prophylaxis Methods 0.000 claims abstract description 4
- 239000000341 volatile oil Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 230000036571 hydration Effects 0.000 claims description 3
- 238000006703 hydration reaction Methods 0.000 claims description 3
- 235000013628 Lantana involucrata Nutrition 0.000 claims description 2
- 235000006677 Monarda citriodora ssp. austromontana Nutrition 0.000 claims description 2
- 240000007673 Origanum vulgare Species 0.000 claims description 2
- 244000178231 Rosmarinus officinalis Species 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 229920005862 polyol Polymers 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 230000002195 synergetic effect Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000000470 constituent Substances 0.000 claims 2
- 230000003020 moisturizing effect Effects 0.000 claims 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims 1
- 240000002657 Thymus vulgaris Species 0.000 claims 1
- 235000007303 Thymus vulgaris Nutrition 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims 1
- 230000002538 fungal effect Effects 0.000 claims 1
- 229960002591 hydroxyproline Drugs 0.000 claims 1
- 238000005470 impregnation Methods 0.000 claims 1
- 230000001926 lymphatic effect Effects 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- 150000003077 polyols Chemical class 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000000434 stratum corneum Anatomy 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000001585 thymus vulgaris Substances 0.000 claims 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims 1
- 201000002282 venous insufficiency Diseases 0.000 claims 1
- 230000004089 microcirculation Effects 0.000 abstract description 2
- 230000002500 effect on skin Effects 0.000 abstract 2
- 210000004204 blood vessel Anatomy 0.000 abstract 1
- 239000011885 synergistic combination Substances 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 3
- 208000005156 Dehydration Diseases 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 244000146462 Centella asiatica Species 0.000 description 1
- 235000004032 Centella asiatica Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 244000178870 Lavandula angustifolia Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 241000378467 Melaleuca Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 206010003230 arteritis Diseases 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 230000003683 cardiac damage Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000000500 vasculoprotective effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
NOUVELLES COMPOSITIONS PHARMACEUTIQUES DESTINEES NOTAMMENT A L'HYGIENE DESNEW PHARMACEUTICAL COMPOSITIONS INTENDED IN PARTICULAR FOR HYGIENE OF
PIEDS DES DIABETIQUESDIABETIC FEET
L'invention se rapporte au domaine de la chimie et en particulier à celui de la chimie thérapeutique. Elle a plus particulièrement pour objet de nouvelles compositions pharmaceutiques présentées notamment pour l'usage topique, nuvelles compositions pharmaceutiques destinées notamment à l'hygiène et à la prophylaxie des pieds des diabétiques. 10 Elle se rapporte précisément à des compositions dermatologiques destinées à traiter ou à prévenir les incidents ou les accidents cutanés liés à la survenue de lésions dénommées pied diabétique. Le diabète est une affection atteignant un nombre de plus en plus grand de sujets de par le monde. Ce nombre croissant émeut à juste titre les autorités médicales et gouvernementales mondiales. The invention relates to the field of chemistry and in particular to that of therapeutic chemistry. It relates more particularly to new pharmaceutical compositions presented in particular for topical use, new pharmaceutical compositions intended in particular for the hygiene and prophylaxis of the feet of diabetics. 10 It relates specifically to dermatological compositions intended to treat or prevent incidents or skin accidents linked to the occurrence of lesions called diabetic foot. Diabetes is a condition that affects more and more people around the world. This growing number rightly moves the world's medical and government authorities.
L'OMS dénombre actuellement 150 millions de diabétiques dans le monde; ce nombre sera 20 probablement doublé dans deux décennies. WHO currently has 150 million diabetics worldwide; that number will likely double in two decades.
En France, on relève près de 3 millions de diabétiques dont 800.000 ignorent leur état. In France, there are nearly 3 million diabetics, 800,000 of whom are unaware of their condition.
On sait que les conséquences du diabète sont essentiellement des affections liées à des 25 troubles de la micro- et/ou de la macrocirculation, responsables de la morbidité de la maladie diabétique. Liées à la micro-circulation sont les atteintes rénales, oculaires, cardiaques, cérébrales. Liées à la macro-circulation, sont les atteintes artéritiques des gros vaisseaux It is known that the consequences of diabetes are essentially conditions linked to micro- and / or macrocirculation disorders responsible for the morbidity of diabetic disease. Linked to micro-circulation are kidney, eye, heart and brain damage. Linked to macro-circulation, are arteritic lesions of the large vessels
aorte, artères des membres inférieurs distales et/ou proximales. aorta, arteries of the distal and / or proximal lower limbs.
L'artérite des pieds est un risque majeur chez le diabétique qui conduirait à 10.000 amputations par an. La vulnérabilité du pied diabétique a pour cause une double atteinte Arteritis of the feet is a major risk in diabetics which would lead to 10,000 amputations per year. The vulnerability of the diabetic foot is due to a double attack
possible artérielle et neuropathique. possible arterial and neuropathic.
En effet, sur une zone agressée; blessée, infection: oedème, inflammation, infection surviennent facilement chez les diabétiques. De tels incidents requièrent une irrigation suffisante, ce que ne peuvent apporter des artères rétrécies au flux sanguin insuffisant. Ajouté à cela, le manque de sensibilité régionale occasionnée par une neuropathie d'un patient 5 diabétique qui ne ressent pas la douleur et qui ne réaliserait pas même la présence d'une plaie éventuelle. Indeed, on an attacked area; injured, infection: edema, inflammation, infection occur easily in diabetics. Such incidents require sufficient irrigation, which cannot be done by narrowed arteries with insufficient blood flow. Added to this, the lack of regional sensitivity caused by neuropathy of a diabetic patient who does not feel pain and who would not even realize the presence of a possible wound.
On comprend ainsi l'extrême importance à titre prophylactique d'une hygiène rigoureuse du pied. Cette hygiène doit viser à se prémunir contre une atteinte microbienne ou mycosique, 10 elle vise en même temps au maintien d'une intégrité dermo-épidermique constante à titre prophylactique. Cette prophylaxie commence par la recommandation d'un lavage rigoureux des pieds, suivi d'un séchage soigné. De plus, il faut lutter contre les phénomènes possibles de déshydratation cutanée, plus fréquents qu'à l'inverse d'une dyshydrose, ces phénomènes pouvant constituer un terrain propice à une quelconque infection. 15 C'est dans ce contexte que vient s'inscrire l'utilisation recommandée d'une préparation protectrice à visée prophylactique, qui tient compte des facteurs susceptibles d'être impliqués We can therefore understand the extreme prophylactic importance of rigorous foot hygiene. This hygiene must aim to protect against microbial or mycotic damage, 10 it aims at the same time to maintain a constant dermo-epidermal integrity on a prophylactic basis. This prophylaxis begins with the recommendation of a rigorous washing of the feet, followed by careful drying. In addition, it is necessary to fight against the possible phenomena of cutaneous dehydration, more frequent than on the contrary of a dyshydrosis, these phenomena being able to constitute a favorable ground for any infection. 15 It is in this context that the recommended use of a protective preparation for prophylactic purposes comes into play, which takes into account the factors likely to be involved.
dans la survenue d'incidents ou d'accidents cutanés chez le pied du diabétique. in the occurrence of incidents or skin accidents in the diabetic's foot.
La présente invention consiste donc en ce qu'on préconise à titre prophylactique une préparation dotée d'une triple activité synergique The present invention therefore consists in that a prophylactic preparation is recommended having a triple synergistic activity
La première agit sur les phénomènes de déshydratation dermo-épidermique. La deuxième agit sur les phénomènes circulatoires capillaro-veineux. La troisième va avoir une activité 25 antiseptique en prévention des risques d'atteintes bactériennes et/ou mycosiques. The first acts on the dermo-epidermal dehydration phenomena. The second acts on capillary-venous circulatory phenomena. The third will have an antiseptic activity in prevention of the risks of bacterial and / or mycotic attacks.
L'invention se rapporte donc à la réalisation de compositions pharmaceutiques concernant en premier lieu l'action favorisante sur l'hydratation dermo-épidermique, qui comporte au moins l'un des principes actifs suivants - l'hydantoine - le glycérol - les polyols l'hydroxypolysilane notamment associés en outre dans la formule à environ 40 % d'eau d'une source minérale reconnue pour son efficacité en dermatologie, comme par exemple l'eau d'Uriage, l'eau de Molitg-les-bains, The invention therefore relates to the production of pharmaceutical compositions concerning in the first place the promoting action on the dermo-epidermal hydration, which comprises at least one of the following active principles - hydantoin - glycerol - polyols l hydroxypolysilane especially associated in addition in the formula with approximately 40% water from a mineral source recognized for its effectiveness in dermatology, such as for example Uriage water, Molitg-les-bains water,
l'eau de Dax, de Laroche Posay et d'Avène notamment. the water of Dax, Laroche Posay and Avène in particular.
En ce qui concerne l'action vasculo-protectrice on incorpore encore dans les compositions selon l'invention un ou plusieurs des produits suivants: - les vitamines A et E - des anti-oxydants du type citroflavonodes - un extrait de Centella asiatica 10 - la Rutine... notamment En ce qui concerne l'action antiseptique, on incorpore aux compositions une ou des huiles essentielles aux actions bactéricides, bactériostatiques fongicides reconnues, et notamment, l'huile essentielle de Romarin, l'huile essentielle d'Origan, l'huile essentielle de Melaleuca et 15 l'huile essentielle de Lavande, et enfin en association une solution de gluconate de Zinc à As regards the vasculo-protective action, one or more of the following products are also incorporated into the compositions according to the invention: - vitamins A and E - antioxidants of the citroflavonodes type - an extract of Centella asiatica 10 - the Rutin ... in particular As regards the antiseptic action, one or more essential oils are incorporated into the compositions with bactericidal, bacteriostatic fungicidal actions recognized, and in particular, essential oil of Rosemary, essential oil of Oregano, l essential oil of Melaleuca and essential oil of Lavender, and finally in combination with a solution of Zinc gluconate
%à10%.% To 10%.
Les compositions selon l'invention sont incorporées dans un excipient ou un véhicule inerte non allergisant adapté à l'usage dermatologique. 20 The compositions according to the invention are incorporated in an inert non-allergenic excipient or vehicle suitable for dermatological use. 20
4 28447164 2844716
Claims (7)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0211712A FR2844716B1 (en) | 2002-09-23 | 2002-09-23 | NOVEL PHARMACEUTICAL COMPOSITIONS, IN PARTICULAR FOR FOOD HYGIENE OF DIABETICS |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0211712A FR2844716B1 (en) | 2002-09-23 | 2002-09-23 | NOVEL PHARMACEUTICAL COMPOSITIONS, IN PARTICULAR FOR FOOD HYGIENE OF DIABETICS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FR2844716A1 true FR2844716A1 (en) | 2004-03-26 |
| FR2844716B3 FR2844716B3 (en) | 2004-10-29 |
| FR2844716B1 FR2844716B1 (en) | 2008-11-21 |
Family
ID=31970881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR0211712A Expired - Fee Related FR2844716B1 (en) | 2002-09-23 | 2002-09-23 | NOVEL PHARMACEUTICAL COMPOSITIONS, IN PARTICULAR FOR FOOD HYGIENE OF DIABETICS |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2844716B1 (en) |
Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2315258A1 (en) * | 1975-06-23 | 1977-01-21 | Fisons Ltd | Cosmetic cream for chapped and dry skin - including olive oil, liquid silicone, emulsifying wax, sequestrant, water and glycerol |
| DE3507791A1 (en) * | 1984-03-07 | 1985-09-26 | Roshdy Ismail | Composition for protecting the skin |
| WO1998002138A1 (en) * | 1996-07-12 | 1998-01-22 | Indústria e Comércio de Cosméticos Natura Ltda. | Desiccant composition, in emulsion form, for the skin |
| RU2112548C1 (en) * | 1995-11-03 | 1998-06-10 | Рязанский государственный медицинский университет им.акад.И.П.Павлова | Preparation for suppurative wound treatment at diabetes mellitus background |
| WO1998051291A1 (en) * | 1997-05-13 | 1998-11-19 | Remacle Jose | Use of a pharmaceutical composition for treating and/or preventing ischemia |
| US5869062A (en) * | 1997-05-27 | 1999-02-09 | Oliver; Benjamin | Skin treatment composition |
| RU2146921C1 (en) * | 1997-11-05 | 2000-03-27 | Рязанский областной клинический кожно-венерологический диспансер | Ointment composition stimulating epithelium regeneration |
| WO2001017484A2 (en) * | 1999-09-07 | 2001-03-15 | D.T.R. Dermal Therapy Research Inc. | Topical urea composition |
| US20010005510A1 (en) * | 1997-11-13 | 2001-06-28 | Dona Garofano | Anti-fungal composition |
| JP2001206832A (en) * | 2000-01-25 | 2001-07-31 | Kao Corp | Cosmetics |
| WO2002047680A2 (en) * | 2000-12-15 | 2002-06-20 | Galileo Laboratories, Inc. | Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia |
| WO2002049575A2 (en) * | 2000-12-21 | 2002-06-27 | The Quigley Corporation | Method and composition for the treatment of diabetic neuropathy |
| JP2002212052A (en) * | 2001-01-15 | 2002-07-31 | Hajime Ito | External preparation |
| WO2002058640A1 (en) * | 2001-01-23 | 2002-08-01 | Harris Dennis H | Topical therapeutic skin care system |
-
2002
- 2002-09-23 FR FR0211712A patent/FR2844716B1/en not_active Expired - Fee Related
Patent Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2315258A1 (en) * | 1975-06-23 | 1977-01-21 | Fisons Ltd | Cosmetic cream for chapped and dry skin - including olive oil, liquid silicone, emulsifying wax, sequestrant, water and glycerol |
| DE3507791A1 (en) * | 1984-03-07 | 1985-09-26 | Roshdy Ismail | Composition for protecting the skin |
| RU2112548C1 (en) * | 1995-11-03 | 1998-06-10 | Рязанский государственный медицинский университет им.акад.И.П.Павлова | Preparation for suppurative wound treatment at diabetes mellitus background |
| WO1998002138A1 (en) * | 1996-07-12 | 1998-01-22 | Indústria e Comércio de Cosméticos Natura Ltda. | Desiccant composition, in emulsion form, for the skin |
| WO1998051291A1 (en) * | 1997-05-13 | 1998-11-19 | Remacle Jose | Use of a pharmaceutical composition for treating and/or preventing ischemia |
| US5869062A (en) * | 1997-05-27 | 1999-02-09 | Oliver; Benjamin | Skin treatment composition |
| RU2146921C1 (en) * | 1997-11-05 | 2000-03-27 | Рязанский областной клинический кожно-венерологический диспансер | Ointment composition stimulating epithelium regeneration |
| US20010005510A1 (en) * | 1997-11-13 | 2001-06-28 | Dona Garofano | Anti-fungal composition |
| WO2001017484A2 (en) * | 1999-09-07 | 2001-03-15 | D.T.R. Dermal Therapy Research Inc. | Topical urea composition |
| JP2001206832A (en) * | 2000-01-25 | 2001-07-31 | Kao Corp | Cosmetics |
| WO2002047680A2 (en) * | 2000-12-15 | 2002-06-20 | Galileo Laboratories, Inc. | Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia |
| WO2002049575A2 (en) * | 2000-12-21 | 2002-06-27 | The Quigley Corporation | Method and composition for the treatment of diabetic neuropathy |
| JP2002212052A (en) * | 2001-01-15 | 2002-07-31 | Hajime Ito | External preparation |
| WO2002058640A1 (en) * | 2001-01-23 | 2002-08-01 | Harris Dennis H | Topical therapeutic skin care system |
Non-Patent Citations (9)
| Title |
|---|
| DATABASE WPI Section Ch Week 199952, Derwent World Patents Index; Class B05, AN 1999-608972, XP002376160 * |
| DATABASE WPI Section Ch Week 200059, Derwent World Patents Index; Class B05, AN 2000-617480, XP002376161 * |
| DATABASE WPI Section Ch Week 200279, Derwent World Patents Index; Class A96, AN 2002-726494, XP002376158 * |
| DORMAN H J D ET AL: "Antimicrobial agents from plants: Antibacterial activity of plant volatile oils", JOURNAL OF APPLIED MICROBIOLOGY, vol. 88, no. 2, February 2000 (2000-02-01), pages 308 - 316, XP008037266, ISSN: 1364-5072 * |
| ISCAN G ET AL: "Antimicrobial screening of mentha piperita essential oils", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 50, 2002, pages 3943 - 3946, XP002984318, ISSN: 0021-8561 * |
| MARINO MARILENA ET AL: "Impedance measurements to study the antimicrobial activity of essential oils from Lamiaceae and Compositae", INTERNATIONAL JOURNAL OF FOOD MICROBIOLOGY, vol. 67, no. 3, 5 August 2001 (2001-08-05), pages 187 - 195, XP007900385, ISSN: 0168-1605 * |
| MOELLER H ET AL: "WIRKUNGEN VON VITAMIN E AUF DIE HAUT BEI TOPISCHER ANWENDUNG", 1989, FETT WISSENSCHAFT TECHNOLOGIE- FAT SCIENCE TECHNOLOGY, CONRADIN INDUSTRIEVERLAG. LEINFELDEN ECHTERDINGEN, DE, PAGE(S) 295-305, ISSN: 0931-5985, XP002043320 * |
| PATENT ABSTRACTS OF JAPAN vol. 2000, no. 24 11 May 2001 (2001-05-11) * |
| PATTNAIK S ET AL: "ANTIBACTERIAL AND ANTIFUNGAL ACTIVITY OF AROMATIC CONSTITUENTS OF ESSENTIAL OILS", MICROBIOS, CAMBRIDGE, GB, vol. 89, no. 358, 1997, pages 39 - 46, XP008005194, ISSN: 0026-2633 * |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2844716B3 (en) | 2004-10-29 |
| FR2844716B1 (en) | 2008-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0091368B1 (en) | Compositions capable of fighting transpiration harm and inconveniences | |
| US20140287064A1 (en) | Compositions for improving the appearance and/or treating fungal infections of nails, mucus membranes and the integument | |
| US20110236503A1 (en) | Topical Skincare Composition | |
| FR2504551A1 (en) | AROMATIC COMPOSITIONS HAVING BIOLOGICAL PROPERTIES AND MEDICINES CONTAINING THEM | |
| US20070253943A1 (en) | Compositions for Topical Treatment | |
| US20240269150A1 (en) | Wound treatment composition | |
| FR2791262A1 (en) | COMPOSITIONS BASED ON CHONDROITINE AND CHITOSAN FOR THE PROTECTION, TREATMENT OR REPLACEMENT OF CONNECTIVE TISSUES | |
| FR2591109A1 (en) | DRUG COMPOSITION BASED ON NATURAL OIL OF VEGETABLE ORIGIN FOR USE IN THE TREATMENT OF HERPES. | |
| FR2844716A1 (en) | NEW PHARMACEUTICAL COMPOSITIONS INTENDED IN PARTICULAR FOR DIABETIC FOOT HYGIENE | |
| EP2068896A1 (en) | Ionic hypertonic solutions based on undiluted seawater, their use as pharmaceutical compositions or medication and for preparing medication intended for treating nasal congestion | |
| JP2017534689A (en) | Methods for the prevention and treatment of acne | |
| FR2758724A1 (en) | Controlling cellulite and fat deposition | |
| US20080145461A1 (en) | Formulation and method of making a topical pain relief composition | |
| EP0391780B1 (en) | Anti-itching composition | |
| EP2509584A1 (en) | Pharmaceutical composition for treating cutaneous burns | |
| EP3506876B1 (en) | Composition for nail fungus | |
| EP2309981A2 (en) | Dermatological composition that can be used in particular for the care and prevention of eschars | |
| US20130034618A1 (en) | Compositions for treating the integument | |
| EP0884948B1 (en) | Antiseptic compositions containing chlorobutanol and chlorhexidine | |
| BE1015498A5 (en) | COMPOSITION AND USE OF THE IODE PUR DISSOLVED IN ESSENTIAL OIL MELALEUCA alternifolia AND / OR MELALEUCA quinquinervia. | |
| FR3127397A1 (en) | Aqueous solution based on Syzygium aromaticum, method of preparation and associated uses | |
| EP0225833A2 (en) | Veterinary medicinal composition, particularly for the treatment of locomotory system diseases or for the preparation towards the effort and the recovery of, for example, sporting horses or hunting dogs especially sporting dogs | |
| FR2725901A1 (en) | Topical compsn. contg. calcium salt | |
| FR2918278A1 (en) | USE OF OLEOCANTHAL IN THE TREATMENT OF SKIN INFLAMMATION. | |
| FR2848114A1 (en) | Cosmetic or dermatological composition used for genito-crural and perineo-gluteal hygiene, prophylaxis and therapy comprises hinokitiol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RN | Application for restoration | ||
| FC | Decision of inpi director general to approve request for restoration | ||
| MV | Notification of grant is cancelled |
Free format text: BOPI DE PUBLICATION N: 04/44 PAGES: 211 PARTIE DU BULLETIN CONCERNEE: BREVETS D'INVENTION, CERTIFICATS D'UTILITE, CERTIFICATS D'ADDITION DELIVRES NATURE DU TITRE ET N: CERTIFICAT D'UTILITE N 2844716 IL Y A LIEU DE SUPPRIMER: LA DECISION DE DELIVRANCE DU CERTIFICAT D UTILITE A ETE RAPPORTEE. EN CONSEQUENCE LA MENTION DE DELIVRANCE PUBLIEE AU BOPI 04/44 DOIT ETRE TENUE POUR NULLE ET NON AVENUE LA PROCEDURE DE DELIVRANCE DE LA DEMANDE DE BREVET A ETE REPRISE |
|
| ST | Notification of lapse |
Effective date: 20110531 |